Records containing: Non-small Cell Lung Cancer

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2024-12-19
  A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies
• CLINICAL_TRIALS study record update · 2024-12-16
  A Prospective, Single-arm, Multicenter, Phase II Clinical Study on Envafolimab Combined With Disitamab Vedotin And Carboplatin for Resectable, Stage II-III, HER2-Mutant Non-Small Cell Lung Cancer
• CLINICAL_TRIALS study record update · 2024-12-16
  A Phase 1, Multi-Center, Dose Escalation, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors
• CLINICAL_TRIALS study record update · 2024-12-16
  A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.
• CLINICAL_TRIALS study record update · 2024-12-16
  A Phase 3, Randomised, Double-blind Study to Compare the Efficacy, Safety, PK and Immunogenicity Between SB8 (Proposed Bevacizumab Biosimilar) and Avastin® in Subjects With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2024-12-13
  A Phase 1, Open-label, Non-Randomized Study to Assess the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer
• CLINICAL_TRIALS study record update · 2024-12-12
  Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLC
• CLINICAL_TRIALS study record update · 2024-12-12
  Tumor-specific Effector T Cells in Non-small Cell Lung Cancer
• CLINICAL_TRIALS study record update · 2024-12-12
  A Prospective, Phase II Study of MR-Linac Guided Adaptive Fractionated Stereotactic Radiotherapy for Brain Metastases From Non-small Cell Lung Cancer
• CLINICAL_TRIALS study record update · 2024-12-09
  Prevalence of Brain Metastases and Impact on Survival in Metastatic Non-small Cell Lung Cancer by Line of Treatment
• CLINICAL_TRIALS study record update · 2024-11-26
  A Prospective, Open-label, Single-arm, Phase II Trial Investigating the Efficacy and Safety of Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients
• CLINICAL_TRIALS study record update · 2024-11-25
  Efficacy and Safety of Aumolertinib with or Without Chemotherapy As First-line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing Epidermal Growth Factor Receptor Mutations: a Randomized, Controlled, Open-label, Phase 3 and Multicenter Clinical Study
• CLINICAL_TRIALS study record update · 2024-11-21
  A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
• CLINICAL_TRIALS study record update · 2024-11-14
  An Open-label Study of the Oral Administration of ASP8273 in Patients With Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
• CLINICAL_TRIALS study record update · 2024-11-07
  A Multicenter, Single-Arm Pilot Study of Immune Checkpoint Inhibitors in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Who Had Long-Term (Two Years or Longer) Response to First-Line Immunotherapy
• CLINICAL_TRIALS study record update · 2024-11-07
  Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage Non-small Cell Lung Cancer HAMLET Study
• CLINICAL_TRIALS study record update · 2024-11-07
  Efficacy and Safety of Almonertinib Versus Placebo as Adjuvant Therapy for Subjects With Resected Stage II-IIIB NSCLC Harboring EGFR-sensitive Mutations: A Randomized, Controlled, Double-blind, Phase 3 and Multicenter Clinical Study
• CLINICAL_TRIALS study record update · 2024-11-04
  A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
• CLINICAL_TRIALS study record update · 2024-11-04
  Phase 3 Multicentre, Prospective, Interventional Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit, From Patients With Non-Small Cell Lung Cancer, Screened in Clinical Study (Protocol No. 20190009).
• CLINICAL_TRIALS study record update · 2024-10-28
  Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer. a Randomised Phase III Trial
• CLINICAL_TRIALS study record update · 2024-10-24
  Test-retest Evaluation of [18F]F-AraG PET in Non-small Cell Lung Cancer (NSCLC) Patients
• CLINICAL_TRIALS study record update · 2024-10-23
  An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 / 2 Study of INBRX-105 and INBRX-105 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
• CLINICAL_TRIALS study record update · 2024-10-18
  FDG PET/CT Radiomics Analyses of Lung Cancer Patients Treated With Immunotherapy
• CLINICAL_TRIALS study record update · 2024-10-16
  A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer
• CLINICAL_TRIALS study record update · 2024-10-15
  A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable Locally Advanced or Metastatic Cancer